Interpreting Emerging Evidence in ATTR-CM: What’s New From ACC 2026?
Dr Margot Davis reviews the 54-month results from the ATTRibute-CM open-label extension, evaluating the long-term impact of continuous versus delayed acoramidis treatment on serum TTR levels and heart failure-related health status. This episode highlights how early intervention with this TTR stabiliser preserves functional capacity and disease control in patients with ATTR-CM.
Filmed at ACC 2026, these expert-led videos presented by Dr Margot Davis (University of British Columbia, Vancouver, CA) provide a focused overview of the evolving therapeutic landscape for transthyretin amyloid cardiomyopathy (ATTR-CM). The series examines the clinical utility of near-complete TTR stabilisation with acoramidis, drawing on new data from the ATTRibute-CM trial and its long-term open-label extension.
Together, the sessions explore the critical relationship between early serum TTR increases and improved patient-reported outcomes, while reviewing survival and safety data out to 54 months. By comparing continuous therapy with delayed initiation, this programme highlights how recent evidence can be translated into practical care to optimise disease control and survival in a contemporary ATTR-CM population.
Key Learning Objectives
- Describe the relationship between TTR stabilisation and health status
- Recall the impact of achieving early TTR stabilisation
- Recall long-term efficacy and safety of acoramidis to 54 months
Target Audience
- Heart Failure
- Cardiologists
- Cardiovascular Specialists
- Geriatricians
- Neurologists
- Hematologists/Oncologists
- Internal Medicine Physicians
- Echocardiographers and Cardiac Imagers
- Specialist Heart Failure Nurses and Pharmacists
More from this programme
Part 1
Long-Term Effects of Acoramidis on Serum TTR and Health Status in ATTR-CM
Dr Margot Davis reviews the 54-month results from the ATTRibute-CM open-label extension, evaluating the long-term impact of continuous versus delayed acoramidis treatment on serum TTR levels and heart failure-related health status. This episode highlights how early intervention with this TTR stabiliser preserves functional capacity and disease control in patients with ATTR-CM.
Part 2
Association Between Early Serum TTR Stabilisation and Health Status in ATTR-CM
Dr Margot Davis investigates the relationship between early serum TTR stabilisation and long-term quality of life in patients with ATTR-CM. This episode reviews findings from the ATTRibute-CM trial demonstrating how rapid TTR increases at day 28 correlate with preserved heart failure-related health status at month 30.
Part 3
Long-Term Effects of Acoramidis on Mortality and Safety in ATTR-CM: An OLE Analysis of ATTRibute-CM
Dr Margot Davis reviews the 54-month survival and safety data from the ATTRibute-CM open-label extension, highlighting a significant reduction in all-cause and cardiovascular mortality for patients on continuous acoramidis. This episode explores the long-term impact of early treatment on mortality outcomes and biomarker stability across clinical subgroups, confirming the sustained efficacy and well-tolerated safety profile of this TTR stabiliser.
Part 4
Emerging Stabiliser Data in ATTR-CM: Interpreting Data from ACC 2026
Dr Margot Davis provides a comprehensive synthesis of the new evidence presented at ACC 2026, placing the latest acoramidis data into clinical context. This concluding episode explores how early and sustained TTR stabilisation fundamentally alters the disease trajectory of ATTR-CM, translating into long-term survival benefits and the preservation of patient independence and quality of life.
Faculty Biographies
Margot Davis
Director, University of British Columbia (UBC) Cardiology-Oncology Program, Vancouver General Hospital, Vancouver, Canada
Dr Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul's Hospital, as well as the director of the UBC Cardiology-Oncology Program and a clinical assistant professor at the University of British Columbia (UBC).
Dr Davis is a key panel member of the CCS Cardio-Oncology Guidelines, a secondary panel member of the CCS Heart Failure Guidelines, and co-chair of the CCS/CHFS Position Statement on Cardiac Amyloidosis. She is vice president of the Canadian Cardiac Oncology Network and a member of the Executive Committee of the Board of Directors of the Canadian Heart Failure Society. Her research focuses on cardiac amyloidosis, severe heart failure, and cancer therapy-related heart disease prevention, diagnosis, and management.
Comments